➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
McKinsey
Boehringer Ingelheim
McKesson
Express Scripts

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Insulin glargine; lixisenatide - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for insulin glargine; lixisenatide

Identify potential brand extensions & biosimilar entrants

SponsorPhase
University Hospital TuebingenPhase 4
Medical University of ViennaPhase 3
VU University Medical CenterPhase 4

See all insulin glargine; lixisenatide clinical trials

Recent Litigation for insulin glargine; lixisenatide

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
SANOFI-AVENTIS U.S. LLC v. MYLAN N v.2017-10-24
Allergan Sales, LLC v. Teva Pharmaceuticals USA, Inc.2016-11-30
Sanofi-Aventis U.S. LLC v. Merck Sharp & Dohme Corp.2016-09-16

See all insulin glargine; lixisenatide litigation

PTAB Litigation
PetitionerDate
Pfizer Inc.2019-05-02
Mylan Pharmaceuticals Inc.2018-10-29
Mylan Pharmaceuticals Inc2018-09-10

See all insulin glargine; lixisenatide litigation

Patent Text Search: US Patents for insulin glargine; lixisenatide

These patents were identified by searching patent claims

Supplementary Protection Certificates for insulin glargine; lixisenatide

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB00/022 United Kingdom   Start Trial PRODUCT NAME: INSULIN GLARGINE (LANTUS) OPTIONALLY IN THE FORM OF ESTERS THEREOF OR PHYSIOLOGICALLY TOLERATED SALTS THEREOF.; REGISTERED: UK EU/1/00/134/001 20000609; UK EU/1/00/134/002 20000609; UK EU/1/00/134/003 20000609; UK EU/1/00/134/004 20000609; UK EU/1/00/134/005 20000609; UK EU/1/00/134/006 20000609; UK EU/1/00/134/007 20000609
2013902170499 Italy   Start Trial PRODUCT NAME: INSULINA DEGLUDEC(TRESIBA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/12/807/001-4-5-7-8-9-12-13-15, 20130121
2498802/01 Switzerland   Start Trial PRODUCT NAME: INSULINUM GLARGINUM + LIXISENATIDUM; REGISTRATION NO/DATE: AUTORISATION SWISSMEDIC 66283 05.10.2017
32/2000 Austria   Start Trial PRODUCT NAME: INSULIN ASPART/PROTAMIN
0885961/01 Switzerland   Start Trial PRODUCT NAME: INSULIN GLULISIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57013 02.05.2005
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
AstraZeneca
Baxter
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.